In addition, the severity of pulmonary fibrosis was much lower in the Mecp2 siRNA‐loaded liposomes‐treated group than in the other groups, as shown by the Ashcroft scores (Figure 5c). This evidence concerns the gene MECP2 and pulmonary fibrosis.